Sarennya Pathmanandavel on Muck Rack

Sarennya Pathmanandavel

As seen in: Nature, Journal of Nuclear Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Sarennya

Contact Sarennya, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Predictive value of early PSMA upregulation for the response to enzalutamide ± 177 Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial

|
By Louise Emmett, Mina Swiha, Nathan Papa, Shalini Subramaniam, Megan Crumbaker, Anthony M. Joshua, Andrew Nguyen, Andrew Weickhardt, Sze-Ting Lee, Siobhan Ng, Roslyn Francis, Jeffrey Goh, David Pattison, Sarennya Pathmanandavel, Thomas J. Hope, Narjess Ayati, Michael S Hofman, Shahneen Sandhu, Andrew Martin, Hayley Thomas, Martin R. Stockler, Ian Davis, Claire Niu
| Nature Verified
Abstract Prostate-specific membrane antigen (PSMA) receptor expression alters with androgen blockade in metastatic castrate-resistant prostate cancer (mCRPC). We evaluated the frequency and significance of early PSMA-positron emission tomography (PET) standardized uptake value (SUV) mean change with enzalutamide ± 177Lu-PSMA-617. ENZA-p is a randomized trial. Participants had mCRPC and 68Ga-PSMA positive disease.
Open in Who Shared Issue with article?

Comparison of Posttherapy 4- and 24-Hour [177Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer

|
By Mina Swiha, Sarennya Pathmanandavel, Nathan Papa, Zahra Sabahi
| Journal of Nuclear Medicine Verified
[177Lu]Lu-prostate-specific membrane antigen (PSMA) is an effective treatment for metastatic castration-resistant prostate cancer (mCRPC). [177Lu]Lu-PSMA SPECT/CT 24 h after injection has shown potential as a response biomarker for [177Lu]Lu-PSMA therapy but is not convenient for patients. This study investigated 4-h [177Lu]Lu-PSMA SPECT/CT as an alternative to 24-h [177Lu]Lu-PSMA SPECT/CT for evaluation of treatment response.
Open in Who Shared Issue with article?

The Tyr Phenomenon: A Hypocalcemic Response in High-Volume Treatment Responders to 177Lu-Prostate-Specific Membrane Antigen Therapy

|
By Shejil Kumar, Megan Crumbaker, Christopher Harvey, Sarennya Pathmanandavel
| Journal of Nuclear Medicine Verified
Thank you for your interest in spreading the word on Journal of Nuclear Medicine. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.
Open in Who Shared View Duplicates (2) Issue with article?
See all 6 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified